Skip to main content

Advertisement

Log in

The relationship between postmenopausal women’s sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products

  • Gynecologic Endocrinology and Reproductive Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

To investigate the relationship between postmenopausal women’s sclerostin levels and bone density and the factors that may affect this relationship.

Materials and methods

135 postmenopausal patients’ ages, BMIs, hormonal statuses, BMD values, and smoking, and consumption of coffee and dairy products were compared with their sclerostin levels.

Results

No statistical relationship was found between sclerostin level and age in the group with osteoporosis (p = 0.204, r = −0.305). There was a positive, high-level relationship between sclerostin levels and BMI in the osteoporosis group and it was found to be statistically significant (p < 0.001, r = 0.786). No statistical relationship was found between sclerostin level and age in the non-osteoporosis group with (p = 0.496, r = −0.88). There was a positive, moderate relationship between sclerostin levels and BMI in the non-osteoporosis group and it was found to be statistically significant (p < 0.001, r = 0.505). No statistically significant relationship could be found between sclerostin levels and vitamin D (p = 0.723), PTH (p = 0.112), FSH (p = 0.795), E2 (p = 0.627), TSH (p = 0.517), T3 (p = 0.788), and T4 (p = 0.664) blood levels. No significant difference was found among the groups formed by smoking, consumption of coffee and milk, and dairy products, either (p = 0.405; p = 0.626; p = 0.234, respectively). It was monitored that sclerostin’s negative effect observed on BMD scores was independent from age; however, it had a positive correlation with BMI.

Conclusion

As blood sclerostin levels increase, bone mineral density decreases. This negative effect of sclerostin on bone density increases as BMI increases, too. Effects of sclerostin levels on bone density are independent from age, and they are not affect by levels of vitamin D: PTH, FSH, E2 and thyroid hormones, and daily activities, such as smoking and consumption of coffee and milk and dairy products, either.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. IH N (2001) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7–29, 2000: highlights of the conference. South Med J 94:569–573

    Google Scholar 

  2. Unni S, Yao Y, Milne N, Gunning K, Curtis JR, LaFleur J (2015) An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record database. Osteoporos Int 26(2):581–587

    Article  CAS  PubMed  Google Scholar 

  3. Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD (2014) Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos 9(1):182

    Article  CAS  PubMed  Google Scholar 

  4. Martin TJ (2014) Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab 21(1):8–20

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tella SH, Gallagher JC (2014) Biological agents in management of osteoporosis. Eur J Clin Pharmacol 70(11):1291–1301

    Article  CAS  PubMed  Google Scholar 

  6. van Dinther M, Zhang J, Weidauer SE et al (2013) Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One 8(4):e62295

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lin C, Jiang X, Dai Z et al (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24(10):1651–1661

    Article  CAS  PubMed  Google Scholar 

  8. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16(3):319–327

    Article  PubMed  Google Scholar 

  9. Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19(2):179–192

    Article  CAS  PubMed  Google Scholar 

  10. Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13(4):485–496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group (meeting held in Rome from 22 to 25 June 1992)

  12. Poole KE, van Bezooijen RL, Loveridge N et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844

    CAS  PubMed  Google Scholar 

  13. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24(2):489–494

    Article  CAS  PubMed  Google Scholar 

  14. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Chen Q (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578–588

    Article  CAS  PubMed  Google Scholar 

  15. Fukumoto S, Martin TJ (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20(5):230–236

    Article  CAS  PubMed  Google Scholar 

  16. Wang J, Zhang W, Yu C, Zhang X, Zhang H, Guan Q, Xu J (2015) Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PloS One 10(8):e0134986

    Article  PubMed  PubMed Central  Google Scholar 

  17. Liakou CG, Mastorakos G, Makris K et al (2016) Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study. Endocrine 54(2):543–551

    Article  CAS  PubMed  Google Scholar 

  18. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95(4):1991–1997

    Article  PubMed  PubMed Central  Google Scholar 

  19. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ (2014) Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol 170(4):645–650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M (2011) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97(1):234–241

    Article  PubMed  Google Scholar 

  22. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Cataldo D (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97(5):1737–1744

    Article  CAS  PubMed  Google Scholar 

  23. Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E (2015) Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 438:401–414

    Article  CAS  PubMed  Google Scholar 

  24. Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221–3228

    Article  CAS  PubMed  Google Scholar 

  25. Delanaye P, Cavalier E, Bouquegneau A, Khwaja A (2015) Sclerostin levels in CKD patients: an important, but not definitive, step on the way to clinical use. Kidney Int 88(6):1221–1223

    Article  CAS  PubMed  Google Scholar 

  26. Muftic M, Selimovic EK, Miladinovic K (2013) Osteoporosis-comparative study between quantitative ultrasound of calcaneus and DXA. Med Archives 67(4):289

    Article  Google Scholar 

  27. Oncken C, Prestwood K, Kleppinger A, Wang Y, Cooney J, Raisz L (2006) Impact of smoking cessation on bone mineral density in postmenopausal women. J Women’s Health 15(10):1141–1150

    Article  Google Scholar 

  28. Barrett-Connor E, Chang JC, Edelstein SL (1994) Coffee-associated osteoporosis offset by daily milk consumption: the Rancho Bernardo Study. Jama 271(4):280–283

    Article  CAS  PubMed  Google Scholar 

  29. Lötters, FJB, Lenoir-Wijnkoop I, Fardellone P, Rizzoli R, Rocher E, Poley MJ (2013) Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int 24(1):139–150

    Article  PubMed  Google Scholar 

  30. González-Reimers E, Martín-González C, De la Vega-Prieto MJ, Pelazas-González R, Fernández-Rodríguez C, López-Prieto J, Santolaria-Fernández F (2013) Serum sclerostin in alcoholics: a pilot study. Alcohol Alcohol 48(3):278–282

    Article  PubMed  Google Scholar 

  31. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3):739–742

    Article  CAS  PubMed  Google Scholar 

  32. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Fahrleitner-Pammer A (2011) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97(1):148–154

    Article  PubMed  Google Scholar 

  33. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26(2):373–379

    Article  PubMed  Google Scholar 

  34. Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Khosla S (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1–6

    Article  CAS  PubMed  Google Scholar 

  35. Armamento-Villareal R, Sadler C, Napoli N, Shah K, Chode S, Sinacore DR, Villareal DT (2012) Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res 27(5):1215–1221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, Acton A, Peacock M (2012) Serum leptin, parathyroid hormone, 1, 25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 97(5):1655–1662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Muschitz C, Kocijan R, Marterer C, Nia AR, Muschitz GK, Resch H, Pietschmann P (2014) Sclerostin levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab 100(3):891–901

    Article  PubMed  Google Scholar 

  38. Ivaska KK, Huovinen V, Soinio M, Hannukainen JC, Saunavaara V, Salminen P, Helmiö M, Parkkola R, Nuutila P, Kiviranta R (2016) Changes in bone metabolism after bariatric surgery by gastric bypass or sleeve gastrectomy. Bone. doi:10.1016/j.bone.2016.11.001

    PubMed  Google Scholar 

  39. Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, Tripathy D, Jenkinson C, Folli F (2015) Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism. Diabetes Care 38(8):1509–1517. doi:10.2337/dc14-2989 (Epub 2015 Jun 17)

    Article  CAS  PubMed  Google Scholar 

Download references

Author Contribution

The main author of this study is MNK.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Muberra Namlı Kalem.

Ethics declarations

Conflict of interest

MN Kalem declares that she has no conflict of interest. Z Kalem declares that she has no conflict of interest. N Akgun declares that she has no conflict of interest. B Bakırarar declares that she has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Financial disclosure

The authors declared that this study has received no financial support.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalem, M.N., Kalem, Z., Akgun, N. et al. The relationship between postmenopausal women’s sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products. Arch Gynecol Obstet 295, 785–793 (2017). https://doi.org/10.1007/s00404-017-4288-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-017-4288-x

Keywords

Navigation